A dominant cell and gene therapy (CGT) CDMO, Avid Bioservices, Inc. (NASDAQ: CDMO) has announced it will be going private in a hefty $1.1 billion acquisition by GHO Capital Partners and Ampersand Capital Partners. The deal, an all-cash transaction, is set to shift Avid from a publicly traded company to a lucratively funded and strategically agile private entity. [Read more…]
Best Practices in MSC Culture: Tracking and Reporting Cellular Age Using Population Doubling Level (PDL)
Author: Jon Rowley, RoosterBio
This is a guest post from RoosterBio. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
There has been much discussion in the literature and the blogosphere (here, here, and here) lately about keeping track of cellular age, and there is very good reason for this. First, there are multiple regulatory guidelines that propose tracking the age of cells used in biologics manufacturing. Secondly, it is well documented that cell phenotype and function can be compromised the older a cell is. A few examples from the literature as this relates to human Mesenchymal Stem Cells (hMSCs) are: [Read more…]
Are Cell Therapy Companies Prioritizing Autologous Or Allogeneic Therapies?
This article highlights ten leading cell therapy companies, all of which have promising cell therapy products being evaluated in clinical trials. These 10 companies were chosen because they are market leaders with robust financial funding, novel technologies, and strong therapeutic pipelines. [Read more…]
Colossal Achieves Multiple Scientific Firsts in Progress Towards Thylacine De-Extinction
Successes across the de-extinction pipeline signal that the thylacine project is on track as Colossal continues its global effort to fight the extinction crisis.
Oct 16, 2024, DALLAS & MELBOURNE, Australia — Colossal, the de-extinction and species preservation company, announces numerous breakthrough successes in all stages of the thylacine de-extinction effort that put the company much closer to returning the iconic thylacine to Australia. From the generation of the highest quality ancient genome to date, to breaking records in multiplex genome editing, to innovations in assisted reproductive technologies for marsupials, Colossal’s success in developing de-extinction technologies will not just support the important thylacine effort but will also help combat the world’s extinction crisis. [Read more…]
Leading iPSC Mass Production Equipment Manufacturers
Induced pluripotent stem cells (iPSCs) represent a groundbreaking advancement in biotechnology. iPSCs are a type of pluripotent stem cell generated by reprogramming adult somatic cells to an embryonic-like state, allowing them to differentiate into virtually any cell type in the body. This innovative technology provides a powerful tool for regenerative medicine, disease modeling, and drug discovery by offering a patient-specific source of cells for research and therapeutic applications. [Read more…]
- « Previous Page
- 1
- …
- 85
- 86
- 87
- 88
- 89
- …
- 338
- Next Page »